Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Indian J Exp Biol 47(9):748753 Kawaguchi K, Kaneko N, Fukuda M, Nakano Y, Kimura S, Hara A, Shimizu M (2013) Responses of insulin-like growth factor (IGF)-I and two IGF-binding protein-1 subtypes to fasting and re-feeding, and their relationships with individual growth rates in yearling masu salmon ( Oncorhynchus masou )
mechanism unexplained Relative contributions of direct peptide effects versus downstream IGF-1 actions inadequately characterized Long-term receptor sensitivity and potential for desensitization inadequately studied Individual patient variability in response not well-characterized Potential for differential effects based on endogenous growth hormone status unclear Long-Term Safety Considerations Critical safety questions remain unanswered regarding chronic peptide administration: Cardiovascular safety concerns FDA warnings cite risks of increased heart rate, systemic vasodilation, flushing, and transient hypotension Immunogenicity risks FDA identifies both peptides as potentially immunogenic with risk of serious immune reactions including anaphylaxis Cancer risk theoretical concern that chronic growth hormone/IGF-1 elevation could promote cellular proliferation
COM To view or add a comment, sign in Most people think GLP-1 is a drug
Agarwal A, Prabakaran SA
Diabetologia 55 , 33593368 (2012)
This journey with GLP-1s has been eye-opening for me, not just for the physical changes, but for the deeper understanding of how interconnected our brains and bodies areand how that knowledge could lead to breakthroughs in addiction treatment
US$ 27.69
US$ 20.00
US$ 20.99
US$ 23.45
US$ 26.50
US$ 20.48
US$ 26.50
US$ 26.02
